stockrowOrganon & Co.
OGNHealthcare Drug Manufacturers General
Organon & Co.’s revenue for fiscal 2025 (year ended December 2025) was $6.2 billion, down 2.92% from fiscal 2024.
- Revenue
- −1.75%
- EPS
- +1.64%
- Free cash flow
- +118.8%
- Total debt
- −3.10%
Quarter to September 2026, against a year earlier
Follow OGN
Alert me
Organon & Co. (OGN) Total debt
Organon & Co.'s total debt at the end of fiscal 2025 was $8.6B, unchanged from fiscal 2024. At the end of the quarter to 30 September 2026 it was $8.6B. Over the past ten years it has ranged from $31.0M (fiscal 2020) to $9.1B (fiscal 2021); the current reading is higher than 50% of that period. Organon & Co. ranks 15th of 21 Drug Manufacturers General companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2025 | $8.6B | (2.66%) |
| FY2024 | $8.9B | 1.37% |
| FY2023 | $8.8B | (1.72%) |
| FY2022 | $8.9B | (2.42%) |
| FY2021 | $9.1B | 29,364.52% |
| FY2020 | $31.0M | (73.73%) |
| FY2019 | $118.0M | (20.81%) |
| FY2018 | $149.0M | — |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Sep 2026 | $8.6B | 0.01% |
| Jun 2026 | $8.6B | (0.19%) |
| Mar 2026 | $8.6B | (0.87%) |
| Dec 2025 | $8.6B | (2.08%) |
| 21 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| PFE Pfizer Inc. compare | $62.7B |
| BMY Bristol Myers Squibb Company compare | $42.9B |
| GSK GSK PLC Sponsored ADR compare | $31.9B |
| NVO Novo Nordisk A/S compare | $20.7B |
| SNY Sanofi compare | $20.7B |
| GRFS Grifols, S.A. compare | $10.6B |
| OGN Organon & Co. | $8.6B |
| BIIB Biogen Inc. compare | $7.3B |
| AMRN Amarin Corporation PLC compare | $9.0M |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on OGN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement